


BENEFIT NEWS

WVCH: Stimulant Utilization

August 1, 2018

WVCH continues to be an outlier compared to other Oregon CCOs for cost and total utilization in the adult population for stimulant medication.

Despite the prior authorization process, Willamette Valley Community Health plan continues to be an outlier compared to other Oregon CCOs with respect to not only overall cost, but total utilization and in the adult population (18 and older). Stimulant medications are classified by the DEA as schedule II which means they are considered to have a high risk of abuse and dependence.



"I always check the PDMP before prescribing stimulants or any controlled substance to my patients."

- WVCH Provider

Non-stimulant medications carved out to DMAP:

(This means they are not billed to WVCH, and instead are carved out to the state for coverage)

1. Atomoxetine (Strattera)
2. Guanfacine ER (Intuniv)
3. Clonidine ER (Kapvay)

In This Issue

- WVCH as a prescribing outlier
- Non-stimulant options
- WVCH Expanded formulary. Page 2
- Attached comparison of different formulary formulations.



BENEFIT NEWS

WVCH: Expanded formulary options for the treatment of ADHD

In the fall 2017, the WVCH expanded formulary stimulant options for the treatment of ADHD.

- Age limit increased from 18 to 19 years of age before requiring a PA
- Additional products have been added to the formulary:
 - Mixed amphetamine salts ER capsules
 - Methylphenidate SR (Ritalin SR)
 - Methylphenidate CD (Metadate CD)
 - Methylphenidate LA (Ritalin LA)

All stimulants prescribed to pediatric members under the age of 6 require a prior authorization with documentation of parent behavior training prior to initiation of pharmacotherapy (per Guideline note 20 of the prioritized list). All stimulant formulary medications have a quantity limit.

The preferred formulary options for adults are the immediate release formulation

- Mixed amphetamine salts (Adderall)
- Methylphenidate (Ritalin)

Though many stimulants are available as generic (all formulary stimulants are generic), they can still be costly. In addition, there can be confusion between some of the different dosage forms of the extended release methylphenidate products.

Attached is a comparison of the different formulary methylphenidate formulations.

Questions:

Contact WVCH Customer Service 503-584-2150 or the WVCH Pharmacy Department at 503-371-7701.

View the current WVCH Formulary at WVCHHealth.org on the For Providers page.